Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.
复制标题
DOI:
10.1016/j.chom.2021.10.003
复制
发表时间:
2021-11-10
影响因子:
30.3
通讯作者:
Burgers WA
中科院分区:
文献类型:
--
作者:
Keeton R;Richardson SI;Moyo-Gwete T;Hermanus T;Tincho MB;Benede N;Manamela NP;Baguma R;Makhado Z;Ngomti A;Motlou T;Mennen M;Chinhoyi L;Skelem S;Maboreke H;Doolabh D;Iranzadeh A;Otter AD;Brooks T;Noursadeghi M;Moon JC;Grifoni A;Weiskopf D;Sette A;Blackburn J;Hsiao NY;Williamson C;Riou C;Goga A;Garrett N;Bekker LG;Gray G;Ntusi NAB;Moore PL;Burgers WA
The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naive with those either infected with the ancestral D614G virus or infected in the second wave when Beta predominated. Prior infection significantly boosts spike-binding antibodies, antibody-dependent cellular cytotoxicity, and neutralizing antibodies against D614G, Beta, and Delta; however, neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses are induced after vaccination, regardless of prior infection. T cell recognition of variants is largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination after infection could result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern. Keeton, Richardson, Moyo-Gwete, et al. show that SARS-CoV-2 infection prior to Ad26CoV2.S vaccination significantly boosts cross-reactive ADCC and binding and neutralizing antibodies and moderately boosts T cell responses against variants of concern. Furthermore, the infecting virus spike sequence determines the cross-reactivity of neutralizing responses, with implications for second-generation vaccine design.
登录
查看更多内容
影响因子:
64.5
作者:
Liu C;Ginn HM;Dejnirattisai W;Supasa P;Wang B;Tuekprakhon A;Nutalai R;Zhou D;Mentzer AJ;Zhao Y;Duyvesteyn HME;López-Camacho C;Slon-Campos J;Walter TS;Skelly D;Johnson SA;Ritter TG;Mason C;Costa Clemens SA;Gomes Naveca F;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Dold C;Temperton N;Dong T;Pollard AJ;Knight JC;Crook D;Lambe T;Clutterbuck E;Bibi S;Flaxman A;Bittaye M;Belij-Rammerstorfer S;Gilbert SC;Malik T;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Baillie V;Serafin N;Ditse Z;Da Silva K;Paterson NG;Williams MA;Hall DR;Madhi S;Nunes MC;Goulder P;Fry EE;Mongkolsapaya J;Ren J;Stuart DI;Screaton GR
通讯作者:
Screaton GR
影响因子:
56.9
作者:
Hsieh, Ching-Lin;Goldsmith, Jory A.;McLellan, Jason S.
通讯作者:
McLellan, Jason S.
影响因子:
5.8
作者:
Cleemput, Sara;Dumon, Wim;de Oliveira, Tulio
通讯作者:
de Oliveira, Tulio
DOI:
10.1056/nejmoa2101544
发表时间:
2021-06-10
期刊:
The New England journal of medicine
影响因子:
--
作者:
Sadoff J;Gray G;Vandebosch A;Cárdenas V;Shukarev G;Grinsztejn B;Goepfert PA;Truyers C;Fennema H;Spiessens B;Offergeld K;Scheper G;Taylor KL;Robb ML;Treanor J;Barouch DH;Stoddard J;Ryser MF;Marovich MA;Neuzil KM;Corey L;Cauwenberghs N;Tanner T;Hardt K;Ruiz-Guiñazú J;Le Gars M;Schuitemaker H;Van Hoof J;Struyf F;Douoguih M;ENSEMBLE Study Group
通讯作者:
ENSEMBLE Study Group
影响因子:
64.8
作者:
Alter G;Yu J;Liu J;Chandrashekar A;Borducchi EN;Tostanoski LH;McMahan K;Jacob-Dolan C;Martinez DR;Chang A;Anioke T;Lifton M;Nkolola J;Stephenson KE;Atyeo C;Shin S;Fields P;Kaplan I;Robins H;Amanat F;Krammer F;Baric RS;Le Gars M;Sadoff J;de Groot AM;Heerwegh D;Struyf F;Douoguih M;van Hoof J;Schuitemaker H;Barouch DH
通讯作者:
Barouch DH